Section Arrow
TRVI.NASDAQ
- Trevi Therapeutics
Quotes are at least 15-min delayed:2026/06/01 23:21 EDT
Regular Hours
Last
 13.95
-0.19 (-1.34%)
Day High 
14.175 
Prev. Close
14.14 
1-M High
15.79 
Volume 
1.13M 
Bid
12.5
Ask
15.75
Day Low
13.72 
Open
14.05 
1-M Low
13.11 
Market Cap 
2.01B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 14.05 
20-SMA 14.31 
50-SMA 13.52 
52-W High 16.12 
52-W Low 5.3801 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.32/-0.41
Enterprise Value
2.01B
Balance Sheet
Book Value Per Share
1.21
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
AIMAIM ImmunoTech Inc.0.8986+0.4908+120.35%-- 
GNTAGenenta Science SpA1.65+0.62+60.19%-- 
OTLKOutlook Therapeutics0.843+0.113+15.48%-- 
ADTXAditxt Inc.0.113-0.0042-3.58%-- 
RXRXRecursion Pharmaceuticals3.79+0.2+5.57%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.